Ranking Invest

NewAmsterdam Pharma Company N.V.

Segmento: Healthcare NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Indicadores Básicos

Valor de Mercado

$ 2.73 Bi

IVR

0.14

IVR2

-0.17

Índices de Previsibilidade

Faturamento

1.16

Lucro

1.23

Margem

0.87

Índices de Tendência

Faturamento

-1.11

Lucro

-7.67

Margem

-5.87

Índices de Endividamento

DIV/PAT

-0.96

DIV/L4T

3.99

Dívida Líquida

-$ 748.03 Mi

Patrimônio Líquido

$ 777.36 Mi

L4T

-$ 187.36 Mi

MM4T

-954.45%

Dívidas
Dividendos
Cotação: $24.45

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre